NASDAQ · EMBCHealthcareSurgical Instruments

Embecta financials

$5.76−2.87%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Sep 30
FY24
Sep 30
FY23
Sep 30
FY22
Sep 30
Revenue$1.08B$1.12B$1.12B$1.13B
Gross profit$676.8M$735.2M$749.9M$774.9M
Gross margin62.6%65.5%66.9%68.6%
Operating income$242.1M$166.8M$221.5M$309.6M
Net income$95.4M$78.3M$70.4M$223.6M
Net margin8.8%7.0%6.3%19.8%
Diluted EPS$1.62$1.34$1.22$3.89
EBITDA$282.8M$203.0M$256.6M$400.2M
Operating cash flow$191.7M$35.7M$67.7M$412.2M
Free cash flow$182.4M$19.9M$41.2M$388.6M
Diluted shares58.9M58.3M57.8M57.5M

Balance sheet

Period endSep 30Sep 30Sep 30Sep 30
Cash & equivalents$225.5M$267.5M$326.3M$330.9M
Short-term investments$0.00$0.00$0.00$0.00
Total debt$1.43B$1.61B$1.64B$1.64B
Total assets$1.09B$1.29B$1.21B$1.09B
Total liabilities$1.74B$2.02B$2.04B$1.98B
Shareholders' equity-$650.6M-$738.3M-$821.7M-$891.4M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology